Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lucy Gilbert

Showing results (141-150 of 157) with videos related to

Pageof 16
Sort By:
Future Oncology (London, England)|June 19, 2023
ARTISTRY-7: phase III trial of nemvaleukin alfa plus pembrolizumab vs chemotherapy for platinum-resistant ovarian cancerThomas J Herzog, John L Hays, Joyce N Barlin, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 6, 2026
First-line lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial cancer: 1-Year follow-up after final analysis of the ENGOT-en9/LEAP-001 phase 3 trialChristian Marth, Richard G Moore, Mariusz Bidziński, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 26, 2024
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III TrialChristian Marth, Richard G Moore, Mariusz Bidziński, et al.
Gynecologic Oncology|May 29, 2026
Four-year survival outcomes with dostarlimab plus chemotherapy in mismatch repair deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer in the RUBY trialMatthew A Powell, Henrik Roed, Lyndsay J Willmott, et al.
The New England Journal of Medicine|October 9, 2016
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian CancerMansoor R Mirza, Bradley J Monk, Jørn Herrstedt, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 25, 2024
Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG3031/RUBY trialGiorgio Valabrega, Matthew A Powell, Sakari Hietanen, et al.
Gynecologic Oncology|November 12, 2024
Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)Matthew A Powell, David Cibula, David M O'Malley, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 5, 2025
Quality-adjusted time without symptoms of disease progression or toxicity of treatment in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel versus carboplatin-paclitaxelDana M Chase, Jørn Herrstedt, Eirwen M Miller, et al.
The New England Journal of Medicine|March 27, 2023
Dostarlimab for Primary Advanced or Recurrent Endometrial CancerMansoor R Mirza, Dana M Chase, Brian M Slomovitz, et al.
Lancet (London, England)|September 17, 2024
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trialDomenica Lorusso, Yang Xiang, Kosei Hasegawa, et al.
Pageof 16

Showing results (141-150 of 157) with videos related to

Sort By:
Pageof 16
Future Oncology (London, England)|June 19, 2023
ARTISTRY-7: phase III trial of nemvaleukin alfa plus pembrolizumab vs chemotherapy for platinum-resistant ovarian cancerThomas J Herzog, John L Hays, Joyce N Barlin, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 6, 2026
First-line lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial cancer: 1-Year follow-up after final analysis of the ENGOT-en9/LEAP-001 phase 3 trialChristian Marth, Richard G Moore, Mariusz Bidziński, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 26, 2024
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III TrialChristian Marth, Richard G Moore, Mariusz Bidziński, et al.
Gynecologic Oncology|May 29, 2026
Four-year survival outcomes with dostarlimab plus chemotherapy in mismatch repair deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer in the RUBY trialMatthew A Powell, Henrik Roed, Lyndsay J Willmott, et al.
The New England Journal of Medicine|October 9, 2016
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian CancerMansoor R Mirza, Bradley J Monk, Jørn Herrstedt, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 25, 2024
Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG3031/RUBY trialGiorgio Valabrega, Matthew A Powell, Sakari Hietanen, et al.
Gynecologic Oncology|November 12, 2024
Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)Matthew A Powell, David Cibula, David M O'Malley, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 5, 2025
Quality-adjusted time without symptoms of disease progression or toxicity of treatment in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel versus carboplatin-paclitaxelDana M Chase, Jørn Herrstedt, Eirwen M Miller, et al.
The New England Journal of Medicine|March 27, 2023
Dostarlimab for Primary Advanced or Recurrent Endometrial CancerMansoor R Mirza, Dana M Chase, Brian M Slomovitz, et al.
Lancet (London, England)|September 17, 2024
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trialDomenica Lorusso, Yang Xiang, Kosei Hasegawa, et al.
Pageof 16